Savara (NASDAQ:SVRA) Given Market Outperform Rating at JMP S

Savara (NASDAQ:SVRA – Get Free Report)‘s stock had its “market outperform” rating reiterated by JMP Securities in a research report issued on Monday, Benzinga reports. They currently have a $8.00 target price on the stock. JMP Securities’ price objective would suggest a potential upside of 64.95% from the company’s current price. Separately, Piper Sandler increased […]

Related Keywords

Wellington , New Zealand General , New Zealand , Piper Sandler , Vanguard Group Inc , Savara Inc , Mast Therapeutics Inc , Jennison Associates , Vivo Capital , Wellington Management Group , Get Free Report , Capital Partners , Mast Therapeutics , Savara Daily , Savara , Nasdaq Svra , Svra , Medical , Reiterated Rating , Jmp Securities ,